Patents Issued in July 2, 2019
  • Beraprost-containing patch
    Patent number: 10335389
    Abstract: The present invention provides a patch containing beraprost or a pharmacologically acceptable salt thereof, which achieves high transdermal absorption of beraprost or a pharmacologically acceptable salt thereof and has excellent formulation properties.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: July 2, 2019
    Assignee: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Satoshi Kawakami, Manabu Sogabe, Taiki Shibata
  • Secnidazole for use in the treatment of bacterial vaginosis
    Patent number: 10335390
    Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: July 2, 2019
    Assignee: Symbiomix Therapeutics, LLC
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun
  • Stabilized oxymetazoline formulations and their uses
    Patent number: 10335391
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: July 2, 2019
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Cyclic compounds useful as modulators of TNF ?
    Patent number: 10335392
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: Ring A is 3- to 6-membered carbocyclic or heterocyclic ring; X is CR1 or N; Y is —(CR5R5)m—; Z is —(CR5R5)n—; and q, R1, R2, R3, R4, R6, R7, R8, R9, and R10 are defined herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hai-Yun Xiao, T.G. Murali Dhar, Bin Jiang, Jingwu Duan
  • Nuclear transport modulators and uses thereof
    Patent number: 10335393
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Vincent Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Processes for preparing dolutegravir and cabotegravir and analogues thereof
    Patent number: 10335394
    Abstract: The present invention relates to processes for preparing substances with antiviral activity, in particular the integrase inhibitors dolutegravir and cabotegravir and analogues thereof, as well as intermediates useful in the processes.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Nenad Maras, Lovro Selic, Anja Cusak
  • Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
    Patent number: 10335395
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 2, 2019
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Methods of reversing autonomic nervous system damage
    Patent number: 10335396
    Abstract: Provided herein are methods for preventing, reducing or reversing acute and/or chronic autonomic damage by the suppression of pro-inflammatory cytokines in a subject in need thereof, which methods comprise administering to said subject an effective amount of an antibiotic; polyunsaturated omega-3 fatty acid; and oleic acid; providing VNS (vagal nerve stimulation) to the subject; and placing said subject on an intermittent fasting regimen.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 2, 2019
    Inventor: Patrick M. Nemechek
  • Methods of treating hepatic encephalopathy
    Patent number: 10335397
    Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Salix Pharmaceuticals, Ltd
    Inventor: William Forbes
  • Bioadhesive compositions for intranasal administration of granisetron
    Patent number: 10335398
    Abstract: Sprayable aqueous pharmaceutical compositions containing granisetron or a pharmaceutically salt thereof, and pharmaceutically acceptable inactive ingredients, including tonicity agents, preservatives, and water soluble polymers with bioadhesive properties and/or capable of changing the rheological behavior in relation to ions, pH and temperature. The compositions are intranasally administered to a subject in need thereof in the rapid management and or prevention of nausea and/or vomiting induced by cytotoxic chemotherapy, radiation, or surgery. The composition has the advantages of rapid absorption and onset of action, prolonged drug plasma concentration and pharmacological effects comparable to intravenous infusion, as well as reduced nasal stinging sensation.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 2, 2019
    Assignee: MAXINASE LIFE SCIENCES LIMITED
    Inventors: Yanfeng Wang, Benjamin Tak Kwong Lee, Johnson Yiu Nam Lau
  • Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
    Patent number: 10335399
    Abstract: The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 2, 2019
    Inventors: Iyassu K. Sebhat, Ashok Arasappan, Scott B. Hoyt, Robert R. Wilkening, Duane DeMong
  • Treatment of tauopathies with mGluR5 antagonists
    Patent number: 10335400
    Abstract: The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr307 is induced by the activation of metabotropic glutamate receptor 5 (mGluR5) and leads to hyperphosphorylation of tau. The mGluR5-PP2A axis has a central role in neurofibrillary degeneration and thus is be a therapeutic target for the treatment of tauopathies.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: July 2, 2019
    Assignee: The Research Foundation for Mental Hygiene, Inc.
    Inventor: Khalid Iqbal
  • Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
    Patent number: 10335401
    Abstract: The present invention relates to a compound represented by Formula (I): wherein X is, for example, C(?O); Z is, for example, C(?O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R6 or B; R2 is, for example, hydrogen; R3 is, for example, substituted or unsubstituted alkyl; R4a is, for example, hydrogen; R4b is, for example, hydrogen; R5 is, for example, halogen; R6 is, for example, halogen; R7a is, for example, hydrogen; R7b is, for example, hydrogen; R8 is, for example, hydrogen; R9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 2, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yuji Nishiura, Kana Kurahashi, Naoki Ohyabu, Yoshikazu Sasaki
  • Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
    Patent number: 10335402
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Philip Mitchell, Martin Teall
  • Niacin formulation
    Patent number: 10335403
    Abstract: The present invention provides a composition including an amphiphilic compound capable of self-assembling into a liquid crystalline phase; and a niacin compound. In another aspect, the present invention provides a method for the treatment of a disease state comprising administering a therapeutically effective amount of a pharmaceutical composition incorporating that composition.
    Type: Grant
    Filed: September 16, 2018
    Date of Patent: July 2, 2019
    Assignee: ZEENAR ENTERPRISE PTY LTD
    Inventors: Xavier Mulet, Gregory Yu Foo Szto, David Kannar
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10335404
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 2, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Non-burst releasing pharmaceutical composition
    Patent number: 10335405
    Abstract: Described herein are controlled release oral pharmaceutical compositions and methods for making the same. These pharmaceutical compositions provide a non-burst release of one or more active pharmaceutical ingredients. In particular, a non-burst controlled release oral pharmaceutical composition comprising a capsule and an abuse deterrent controlled release matrix comprising one or more active pharmaceutical ingredients are described.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: July 2, 2019
    Assignee: Patheon Softgels, Inc.
    Inventors: Justin R. Hughey, Chue Hue Yang
  • Opioid compositions resistant to overdose and abuse
    Patent number: 10335406
    Abstract: The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: July 2, 2019
    Assignee: Elysium Therapeutics, Inc.
    Inventor: Thomas E. Jenkins
  • Use of flibanserin in the treatment of obesity
    Patent number: 10335407
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 2, 2019
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Compositions and methods of using nintedanib for improving glaucoma surgery success
    Patent number: 10335408
    Abstract: Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: July 2, 2019
    Assignee: Cloudbreak Therapeutics, LLC
    Inventors: Jinsong Ni, Rong Yang
  • Inhibitors of hepatitis C virus
    Patent number: 10335409
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 2, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Heteroaryl compounds useful as inhibitors of sumo activating enzyme
    Patent number: 10335410
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Administration of ubiquitin-activating enzyme inhibitor and radiation
    Patent number: 10335411
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with radiation. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Neil Bence, Marc Hyer, Michael Milhollen, Vivek Samnotra, Sergio Luis Santillana Soto, Darshan Sappal
  • Method for activating AMPK and the use of adenine
    Patent number: 10335412
    Abstract: The present invention relates to adenine which is useful to activate AMP-activated protein kinase (AMPK) and the use of adenine in the prevention or treatment of conditions or disease and thereby prevent or treat conditions or diseases which can be ameliorated by AMPK in a mammal.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: July 2, 2019
    Assignee: ENERGENESIS BIOMEDICAL CO., LTD
    Inventors: Han-Min Chen, Cheng-Yi Kuo, Chun-Fang Huang, Jiun-Tsai Lin
  • Substituted xanthine derivatives
    Patent number: 10335413
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods
    Patent number: 10335414
    Abstract: The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 2, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Vincent Gattone, Bonnie Blazer-Yost
  • (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
    Patent number: 10335415
    Abstract: Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 2, 2019
    Assignee: MEI PHARMA, INC.
    Inventors: S. David Brown, David J. Matthews
  • Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
    Patent number: 10335416
    Abstract: The disclosure provides a method for treating NPM1-mutated acute myeloid leukemia (AML) by administration of a composition comprising dactinomycin.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: July 2, 2019
    Inventors: Brunangelo Falini, Maria Paola Martelli
  • Thiazideamide derivative and use thereof
    Patent number: 10335417
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: July 2, 2019
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Boqun Lyu, Hongqiang Wang, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xinbo Zhou, Xingzhou Li, Xiaokui Wang
  • Methods and compositions for treating metabolic syndrome
    Patent number: 10335418
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 2, 2019
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Slow release oxysterols and methods of use
    Patent number: 10335419
    Abstract: Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: July 2, 2019
    Assignee: Warsaw Orthopedic, Inc
    Inventors: David S. Scher, Benjamin T. Reves, Roger E. Harrington, Susan J. Drapeau, Jerbrena C. Jacobs
  • Nanoparticle-based tumor-targeted drug delivery
    Patent number: 10335420
    Abstract: An aqueous tumor-targeting liposome nanoparticle composition comprises an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises a legumain-targeting lipid component and polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalently attached to a legumain-binding moiety.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 2, 2019
    Assignee: The Scripps Research Institute
    Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
  • Topical wound care formulation
    Patent number: 10335421
    Abstract: The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: July 2, 2019
    Inventor: Aisha Chaudhry
  • Small molecules that promote skin regeneration
    Patent number: 10335422
    Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: July 2, 2019
    Assignee: International Stem Cell Corporation
    Inventors: Rodolfo Gonzalez, Maxim Poustovoitov, Russell A. Kern
  • Inhibition of HIV infection through chemoprophylaxis
    Patent number: 10335423
    Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 2, 2019
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10335424
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: July 2, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods of treating of bacterial infections with ?-lactamase inhibitors
    Patent number: 10335425
    Abstract: A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one ?-lactam antibiotic and at least one triazolylmethyl boronic acid.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: July 2, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Robert Bonomo, Fabio Prati, Emilia Caselli, Chiara Romagnoli
  • N-acetyl mannosammine as a therapeutic agent
    Patent number: 10335426
    Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 2, 2019
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
  • Tumor prevention and treatment drug and applications thereof
    Patent number: 10335427
    Abstract: The present invention discloses a medicament for the prevention and treatment of tumors, in particular relating to the use of 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) in the manufacturing of a medicament for the prevention and treatment of tumors, and a medicament comprising 8-oxo-dGTP for the prevention and treatment of tumors, and falls within the pharmaceutical field. The 8-oxo-dGTP can be used in the manufacturing of a medicament for at least one of the treatment, prevention and control of tumors. The 8-oxo-dGTP has a significant inhibitory effect on tumorigenesis and tumor cell proliferation for many types of tumors, and can serve as a new candidate medicament for the prevention and treatment of tumors. Animal experiments show that the 8-oxo-dGTP is significantly superior to 5-FU in terms of tumor inhibition, therefore has a good industrial availability and great business and social values.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: July 2, 2019
    Inventor: Jianping Cai
  • P-ethoxy nucleic acids for liposomal formulation
    Patent number: 10335428
    Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: July 2, 2019
    Assignee: BIO-PATH HOLDINGS, INC.
    Inventor: Peter Nielsen
  • Association of beta-glucans and arabinoxylans
    Patent number: 10335429
    Abstract: The present invention relates to an association of beta-glucans from a first cereal and arabinoxylans from a second cereal different from the first cereal, and their use to improve the microbiota balance in human gut.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: July 2, 2019
    Assignee: Generale Biscuit
    Inventors: Isabel Moreira De Almeida, Alexandra Meynier, Maria Urbieta
  • Inulin products with improved nutritional properties
    Patent number: 10335430
    Abstract: Inulin products which consist of a particular mixture of an easily fermentable inulin (EFI) component and a hardly fermentable inulin (HFI) component are provided. The products have advantageous nutritional effects/benefits which include dietary fiber effects, improved mineral absorption, particularly calcium and magnesium, bone mineral density increase, reduction of bone mineral density loss, modulation of lipid metabolism, stimulation of the immune system, and anti-cancer effects.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: July 2, 2019
    Assignee: TIENSE SUIKERRAFFINADERIJ N.V.
    Inventors: Anne Frippiat, Jan Van Loo, Georges Smits
  • Method for producing polyguanidines
    Patent number: 10335431
    Abstract: A method for preparing polycondensation products of guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl or allyl derivatives BA according to the following reaction scheme is provided: wherein X, R1, Gua, Y and Z are as defined in the specification. In the disclosed method, at least one benzyl or allyl derivative BA is subjected to a polycondensation reaction with excessive guanidine, aminoguanidine or diaminoguanidine G upon elimination of HX.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 2, 2019
    Assignee: Sealife Pharma GmbH
    Inventors: Alexander Pretsch, Michael Nagl, Christoph Wiesner, Ralph Hollaus, Miroslav Genov
  • Microporous zirconium silicate for the treatment of hyperkalemia
    Patent number: 10335432
    Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 2, 2019
    Assignee: ZS PHARMA, INC.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Jeff Gilmore
  • NDGA polymers and metal complexes thereof
    Patent number: 10335433
    Abstract: Provided herein are NDGA polymers and metal complexes of such polymers, preferably those metal complexes of the polymers that are insoluble or substantially insoluble in an aqueous solvent, and processes for making the same.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: July 2, 2019
    Assignee: MiMedx Group, Inc.
    Inventor: Thomas J. Koob
  • Ischemic tissue cell therapy
    Patent number: 10335434
    Abstract: The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 2, 2019
    Assignee: University of South Florida
    Inventors: Paul R. Sanberg, Alison E. Willing
  • Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
    Patent number: 10335435
    Abstract: A method is disclosed for delivery of stem cells to the central nervous system, particularly the brain, using an intranasal, injectable approach for the treatment of neurological deficits. The injectable approach employs a syringe to inject a stem cell solution or suspension into mucosal tissue of the nose using endoscopy. The approach provides direct endoscopic visual access to mucosal and sub-mucosal tissue selected for injection and the depth of placement of stem cells within the selected mucosal and sub-mucosal tissue. Placement of stem cells solely within the mucosal and sub-mucosal tissue assures survival of the stem cells and improves the likelihood the stem cells will reach specific sites of damage within the brain. This endoscopic intranasal approach is useful as therapy for patients who may benefit from cellular therapy as a result of stroke, brain trauma, and neurodegenerative conditions.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 2, 2019
    Inventor: Marco Merida
  • Medical treatment composition comprising mammalian dental pulp stem cells
    Patent number: 10335436
    Abstract: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Pluripotent stem cells, other cells, and biologic constituents of the dental pulp may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the pluripotent stem cells, other cells, and biologic constituents of the dental pulp can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 2, 2019
    Inventor: Ray C. Wasielewski
  • Injectable brown adipose microtissues for treatment and prevention of obesity and diabetes
    Patent number: 10335437
    Abstract: Provided are methods, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes by administration of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues to a subject, where the microtissues comprise adipose stem cells and endothelial cells. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3D cell aggregates.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: July 2, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Brian Gillette, Samuel Sia
  • Camelid compound(s), composition(s) and method(s)
    Patent number: 10335438
    Abstract: Described herein are compounds, compositions and methods for the treatment of a subject having cancer, skin conditions, blood flow and/or growth failure. In one aspect of the present invention, there is provided compositions and methods for treating a subject having cancer, skin conditions, blood flow and/or growth failure, comprising fat derived from a camel. There are also described sunscreen and photoprotective compounds, compositions and methods, comprising fat derived from a camel.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 2, 2019
    Inventors: Sabah Abdul Amer Jassim, Atheer Abdulrazzaq Abdulrazeez Al Doori, Richard George Limoges